Yazar "Seçkin, Kerem Doğa" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Sclerosing stromal tumor: a rare ovarian neoplasm
    (2022) Kadiroğulları, Pınar; Seçkin, Kerem Doğa
    Sclerosing stromal tumor (SST) is an extremely rare and distinctive sex cord stromal tumor, which occurs predominantly in the second and third decades of life. SSTs make up 2-6% of ovarian sex-cord stromal tumors. Due to the solid and distinct vascular structure of the tumor, it can be mistaken as a number of malignant ovarian tumors. As this specific neoplasm is very rare, it is not always possible to diagnose the tumor preoperatively with clinical and ultrasonographic findings. Furthermore, histopathological and immunohistochemical analysis does not always confirm the diagnosis. In this case report, clinical findings, histopathological features, and macroscopic appearance during laparoscopy of an SST are presented in a 20-year-old woman with pelvic pain. SST should be considered among the differential diagnosis of women with adnexal masses.
  • Küçük Resim
    Öğe
    The effects of mode of delivery on neonatal screening evaluated by automated auditory brainstem response
    (Acıbadem Mehmet Ali Aydınlar Üniversitesi, 10 Temmuz 2023) Seçkin, Kerem Doğa; Selçuki , Nura Fitnat Topbaş; Aytufan, Zübeyde; Kaya, Cihan; Aygün, Elif Ganime; Kadiroğulları, Pınar
    Background/Purpose: Neonatal hearing screening results are affected by several perinatal and neonatal factors. It is known that false positivity (FP) in the failure of newborn hearing screening increases parental concern and anxiety and has a negative impact on healthcare costs. There are conflicting reports on the effect of the mode of delivery on hearing screening results. This study aimed to investigate the role of mode of delivery on neonatal hearing by comparing the automated auditory brainstem (ABR) results of newborns born with vaginal delivery (VD) or cesarean section (CS) and to identify perinatal and neonatal factors associated with failure of the first neonatal hearing screening test results. Methods: This retrospective case-control study was conducted at our obstetrics clinic between December 2018 and June 2019. Following the exclusion of newborns with incomplete data, with congenital and chromosomal anomalies, with CMV infection, with anatomical deformities involving the face and the ears, and who received their hearing screening <12 hours postpartum and also the exclusion of pregnancies with maternal infections, recurrent pregnancy loss, maternal smoking, and alcohol abuse, a total of 300 newborns, 176 of which were born with VD and 124 were born with CS were included in this study. The neonatal hearing screening was performed with automated ABR. Results: A total of 181 newborns (60.3%) did not have hearing loss whereas in 39.7% hearing loss was detected. When the VD and the CS groups were compared, the mean gravidity and parity were reported to be similar. However, the mean weeks of gestation at birth (p=0.02), 1 min. Apgar score (p=0.007) and 5 min. Apgar score (p=0.005) were significantly lower in the CS group. A 57.4% hearing loss was reported in the VD group and a 64.5% hearing loss was detected in the CS group. The difference between the groups was not significant (p=0.13). The groups were also statistically similar in terms of family history of hearing loss, NICU stay, maternal morbidity and pregnancy complications, p values being 0.58, 0.09, and 0.14, respectively. Conclusion: National Hearing Screening Programs are essential in detecting a hearing failure in newborns in time for a prompt diagnosis and appropriate management of the newborns. However, it is also essential to understand which factors affect newborn hearing and also it is important to minimize FP rates to report accurate results. Our results indicate that mode of delivery does not significantly affect newborn hearing. However, further studies are needed to address the conflicting results in the literature.